Malvern Panalytical
Biopharmaceutical and Drug Development
Ligand Pharmaceuticals' Captisol-enabled, propylene glycol-free drug melphalan has met all the endpoints in a Phase II trial treating patients with multiple myeloma.
Ligand Pharmaceuticals’ Captisol-enabled, propylene glycol-free drug melphalan has met all the endpoints in a Phase II trial treating patients with multiple myeloma.
Developed by Higuchi Biosciences Center, Captisol is a patent-protected, chemically altered cyclodextrin.
The Phase II study compared the safety, tolerability and pharmacokinetic profiles of an intravenous formulation of propylene glycol-free melphalan to the standard multiple myeloma treatment.
The Captisol-enabled drug will provide longer administration durations and slower infusion rates, enabling clinicians to safely achieve a higher dose intensity of pre-transplant chemotherapy.
The trial, conducted in partnership with The University of Kansas Cancer Center, is partially funded by the Kansas Bioscience Authority.
The company plans to begin the 60-patient pivotal trial to further evaluate the safety and efficacy of the drug candidate in 2012.
Biopharmaceutical and Drug Development
Drug Delivery Development for Advanced Oral Formulations
Drug Processing Technology and Laboratory Equipment